Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001193805-25-000672
Filing Date
2025-05-15
Accepted
2025-05-15 19:44:19
Documents
2
Period of Report
2025-05-13

Document Format Files

Seq Description Document Type Size
1 e664519_4-larimar.html 4  
1 e664519_4-larimar.xml 4 6994
2 e664519_ex99.htm EX-99 3553
  Complete submission text file 0001193805-25-000672.txt   12904
Mailing Address 345 PARK AVENUE SOUTH, 12TH FLOOR NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH, 12TH FLOOR NEW YORK NY 10010 2125511600
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (Reporting) CIK: 0001009258 (see all company filings)

State of Incorp.: DE
Type: 4 | Act: 34 | File No.: 001-36510 | Film No.: 25956571

Mailing Address 780 THIRD AVENUE 37TH FLOOR NEW YORK NY 10017
Business Address
Flynn James E (Reporting) CIK: 0001352546 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36510 | Film No.: 25956572

Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Issuer) CIK: 0001374690 (see all company filings)

EIN.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)